Interactions between vardenafil and Disopyramide (disopyramide)
disopyramide and vardenafil (Major Drug-Drug)
GENERALLY AVOID: Vardenafil has been reported to cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in elevated risk of ventricular arrhythmias, including ventricular tachycardia and torsade de pointes, because of additive arrhythmogenic potential related to their effects on cardiac conduction. In a study of the effect of vardenafil on QT interval in 59 healthy volunteers, therapeutic (10 mg) and supratherapeutic (80 mg) doses of vardenafil produced similar increases in QTc interval as moxifloxacin 400 mg, the active control.
MANAGEMENT: Patients treated with class IA (e.g., disopyramide, quinidine, procainamide) or class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents, should avoid using vardenafil.
